secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001628280-25-024911
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q1 net loss $10.2M; OV329 data on track for Q3 2025
---------------------------------------------------------------------

- Cash and equivalents $43.0M at March 31, 2025; expected to fund operations into 2H 2026.
- Topline Phase 1 biomarker and safety data for OV329 (GABA-AT inhibitor) expected in Q3 2025.
- OV350 KCC2 direct activator dosed in Phase 1 in Q1 2025; safety/tolerability results expected Q4 2025.
- Q1 net loss $10.2M ($0.14/sh) vs $11.7M ($0.17/sh) a year ago; total op expenses down 28% to $12.7M.
- Oral KCC2 candidate OV4071 on track to initiate proof-of-concept study in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/0001628280-25-024911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-024911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer